Optimizing the Selection of Novel Therapy for Patients With

Closing out their panel on immunotherapy in non–small cell lung cancer, expert oncologists share key takeaways on the selection of novel therapy in this setting.

Related Keywords

, Recent Updates , Translating Evidence , Clinical Practice , Novel Therapy , Patients With Advanced , Lung Cancer , Non Small Cell Lung Cancer , Nsclc , Trio Therapy , Immunotherapy , Immune Checkpoint Inhibitors , Metastatic Nsclc , Metastatic Lung Cancer , Combination Therapy , Clinical Trials , Selecting Therapy , Selecting Treatment , Pdl1 Expression , Pdl1 Levels , Poseidon Study , Poseidon Trial , Ctla4 , Keynote 598 , Adcs , Antibody Drug Conjugates , Cellular Therapies ,